Harbour BioMed a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, announced that the National Medical Products Administration...
Avanzanite Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company advancing life-changing medicines for rare disease patients across Europe, announces today the appointment of Abdelghani (Abdel) Omari as its first-ever...
HOOKIPA Pharma Inc. a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in the Phase 1b clinical trial...
Azenta, Inc. announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of...
NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom...
Beacon Therapeutics Holdings Limited a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has granted...
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, announced that it has secured a $30 million financing to advance the development of LUT014, an...
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today...
West Pharmaceutical Services, Inc. a global leader in innovative solutions for injectable drug administration, announced the introduction of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format available in multiple...
Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary...
MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION™) technologies for use in malaria vaccines. In addition to HDT Bio's...
Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T...
NGGT Inc., a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced the publication in the journal JAMA Ophthalmology of the results from a dose-escalation study in...
Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years' experience in drug discovery and development across...
Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced the full commercial availability of NTxscribe®, a benchtop, continuous flow RNA in vitro transcription (IVT) and...
Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three...
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...
Dr. Howard Murad, a 1962 graduate of Long Island University's Arnold & Marie Schwartz College of Pharmacy and Health Sciences and an internationally recognized innovator in the science of skin care, is establishing the Dr. Howard Murad '62...